Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | F12 | P00748 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12733730 | 0.73 | CNR2 (0.41) | CNR2NPC1RAB9ARXFP1 | |
| SCHEMBL4902793 | 0.72 | CNR2 (0.36) | CNR2 | |
| SCHEMBL15360059 | 0.70 | — | — | |
| SCHEMBL4901267 | 0.66 | CNR2 (0.49) | CNR2 | |
| SCHEMBL15357747 | 0.60 | — | — | |
| SCHEMBL13400738 | 0.57 | KMT2A (0.37) | — | |
| SCHEMBL21132826 | 0.55 | CA2 (0.33) | — | |
| SCHEMBL12321814 | 0.53 | KMT2A (0.34) | — | |
| SCHEMBL8744680 | 0.52 | KMT2A (0.33) | — | |
| SCHEMBL12856714 | 0.52 | KMT2A (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010008585-A2 | NUCLEASE COMPOSITIONS AND METHODS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2010-01-21 | — | — | WO | claimed |
| US-20100222410-A1 | Nuclease compositions and methods | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2010-09-02 | — | — | US | disclosed |
| US-20100222410-A1 | Nuclease compositions and methods | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2010-09-02 | — | — | US | disclosed |
| WO-2010008585-A2 | NUCLEASE COMPOSITIONS AND METHODS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2010-01-21 | — | — | WO | disclosed |
| US-20080312435-A1 | Imine Compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-12-18 | — | — | US | disclosed |
| EP-1820504-A1 | IMINE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2007-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312435-A1 | Imine Compound | CNR1, CNR2, HRH4 | CNR2 2/4885NPC1 1485/4885RAB9A 841/4885 |
| US-20100222410-A1 | Nuclease compositions and methods | YBX3, RNASEL, RNASEH1 | CNR2 4853/4885NPC1 4644/4885RAB9A 4456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.